No abstract

Objetivo: conocer la prevalencia de enfermedades según el grupo sanguíneo de la población estudiada en la provincia de Cuenca (España). Métodos: estudio observacional, descriptivo, corte transversal y base poblacional. La muestra de 73 personas (39 varones, 34 mujeres), mayores de 60 años. Se identificaron todos los grupos sanguíneos, estudiándolos por edad y género. Resultados: los porcentajes de grupos sanguíneos de la población estudiada por género son 42,6% (grupo A); 42,4% (O); 13% (B) y 1,4% (AB). Predomina el A+ (35,6%), seguido del O+ (27,4%). Se estudia la prevalencia de una determinada enfermedad en función del grupo sanguíneo. En este sentido, se detectan diferencias dentro de un mismo grupo, según el fator Rh. Los grupos Rh positivos padecen más de HTA, insomnio y depresión que los Rh negativos. Los grupos A y O padecen mayor aumento de colesterol que los del grupo B. Los del grupo O tienen más HTA que el resto y el O+ padece mayor porcentaje de anemia (Fe), mientras que los A+ anemia (B12). La osteoporosis es mayor en los grupos negativos que en los positivos, salvo en el grupo AB+. Conclusiones: el grupo sanguíneo con el que nacemos puede condicionar las enfermedades que padeceremos a lo largo de nuestra vida. El ser 0 podría predisponerlos a tener HTA, anemia (Fe), colesterol, enfermedades pulmonares e insomnio, mientras que el A depresión, anemia (B12) y problemas de próstata en varones.

BackgroundMultiple sclerosis (MS) is a chronic demyelinating central nervous disease characterised by a broad spectrum of physical and psychosocial impairments. The MS Quality of Life-54 (MSQoL-54) questionnaire is a health-related quality of life (HRQoL) measure that yields summary scores for physical health composite score (PCS) and mental health composite score (MCS). Both PCS and MCS are expressed on a scale of 0 (poorest QoL) to 100 (best possible QoL).PurposeTo evaluate HRQoL in MS patients calculating PCS and MCS scores. To analyse if there are differences in HRQoL and Expanded Disability Status Scale (EDSS) between disease-modifying therapies (DMTs) of parenteral administration.Material and methodsA prospective study was performed from March to September 2017. MS patients were asked by a hospital pharmacist to complete the MSQoL-54 questionnaire. Clinical data were collected from electronic medical and pharmaceutical records (sex, age, MS disease course, EDSS, disease duration, DMTs). DMTs included were interferon (IFN), glatiramer acetate (GA) and natalizumab. Kruskal–Wallis multivariant analysis with SPSS 15,0 was used for statistical analysis.ResultsNinety patients completed the questionnaire (68% females). Median age was 46 years (IQR 38–55). Eighty-three patients had relapsing remitting multiple sclerosis (RRMS). Median disease duration was 10 years (IQR 5–14). Forty-nine patients were treated with IFN, 22 with GA and 19 with natalizumab. Median EDSS in IFN, GA and natalizumab patients were 1.5, 1.3 and 3 respectively (p<0.001). Median PCS in these patients were 68.3, 54.0 and 48.1 and median MCS 66.0, 63.5 and 45.1. Statistical significant differences between IFN and natalizumab were found in both PCS (p<0.02) and MCS (p<0.001) composite scores.ConclusionThe majority of patients in this study were young females with RRMS. Patients treated with GA and IFN had similar HRQoL. GA and IFN patients had better PCS and MCS scores than natalizumab patients. This could be explained due to higher EDSS values in natalizumab patients. For future research, oral DMTs could be included to investigate if there are any differences in HRQoL with parenteral DMTs.No conflict of interest

BackgroundMultiple Sclerosis (MS) is a chronic demyelinating CNS disease that negatively affects patient quality of life (QoL). The hospital pharmacist dispenses MS disease modifying therapies (DMT) at the outpatient pharmacy.PurposeTo analyse QoL in MS patients who collect firstline DMT at the outpatient pharmacy.Material and methodsA prospective study was performed from March to September 2016. QoL was assessed according to an internal questionnaire. It was designed by a pharmacist and included: demographic characteristics, employment status, home adaptations, mobility, need for support with everyday activities, vacation and leisure habits, and MS medical history during the last year. An Excel database was designed to analyse the results. All MS patients were asked to complete a questionnaire at the outpatient pharmacy when collecting DMT. Firstline DMT included: parenteral drugs (interferon beta-1A and 1B, glatiramer acetate) and oral drugs (dimethyl fumarate, teryflunomide).Results100 of 107 MS patients with the following characteristics completed the questionnaire: mean age 44.83 years (±11.08), 73% women and 91% lived with relatives. 16% were treated with firstline oral DMT. Nearly half of MS patients (45%) were occupationally active. Home adaptations were reported by 13% of patients. 55% did not require support for everyday activities and 79% could move normally. 36% of patients had changed their holiday habits and 58% their leisure activities because of MS. During the last year, 7% of MS patients had suffered a relapse and were admitted to hospital, and 51% reported daily activity disturbances because of MS (mean lost days per year 57). The average number of visits per patient to the neurologist during the last year was 2.ConclusionMost patients included in this study were young active women living with relatives. A high percentage of patients reported an acceptable QoL related to mobility, home adaptations and independence with routine activities, which could be explained by early DMT treatment according to clinical guidelines. Assessing QoL in MS patients is not common in everyday clinical practice. As part of clinical practice, it has the potential to improve communication between the patient and pharmacist, identify frequently overlooked problems and detect those patients most in need of pharmaceutical care.No conflict of interest